EMA Recommends Approval of Amgen's Tarlatamab for Relapsed Small Cell Lung Cancer
核心洞察
The European Medicines Agency (搜索) has recommended marketing authorization for Imdylltra (搜索) (tarlatamab), a bispecific T-cell engager targeting DLL3 (搜索) protein, for adults with relapsed extensive-stage small cell lung cancer (搜索).
Phase 3 trial data showed tarlatamab significantly improved median overall survival to 13.6 months compared to 8.3 months with standard care, representing a 40% reduction in death risk.
The drug represents the first DLL3 (搜索)-targeted therapy in the EU for a cancer type with limited treatment options and poor outcomes following platinum-based chemotherapy relapse.
The European Medicines Agency (搜索) (EMA) has recommended granting marketing authorization for Imdylltra (搜索) (tarlatamab) as a monotherapy treatment for adults with extensive-stage small cell lung cancer (搜索) (ES-SCLC (搜索)) whose disease relapsed during or after initial platinum-based chemotherapy. The recommendation marks a significant milestone for patients with this aggressive cancer type, coming almost two years after the drug's initial approval in the United States.
Breakthrough Mechanism of Action
Imdylltra (搜索) contains tarlatamab, a bispecific antibody that functions as a T-cell engager by simultaneously binding to the DLL3 (搜索) protein on tumor cells and the CD3 (搜索) protein on T cells. This dual targeting brings immune cells into close proximity with cancer cells, activating T cells and triggering the production of inflammatory cytokines and cytotoxic proteins that result in tumor cell death. The drug represents the first therapy in the EU to directly target DLL3, a protein found in 85-96% of SCLC (搜索) tumors but rarely present in healthy cells.
Compelling Clinical Evidence
The EMA's recommendation is based on results from the randomized, open-label phase 3 DeLLphi-304 study involving 509 adults with ES-SCLC (搜索) whose cancer had relapsed after initial platinum-based chemotherapy. Participants received either Imdylltra (搜索) or standard of care chemotherapy including topotecan, lurbinectedin, or amrubicin.
The study demonstrated a significant improvement in median overall survival of 13.6 months for patients treated with Imdylltra (搜索) compared to 8.3 months for those receiving standard care. This translates to a 40% reduction in the risk of death for participants treated with the bispecific antibody. Additionally, median progression-free survival reached 4.2 months with Imdylltra versus 3.2 months with standard care.
Addressing Critical Unmet Need
Small cell lung cancer (搜索) represents a rare, rapidly growing malignancy associated with poor prognosis. While many patients initially benefit from platinum-based chemotherapy, relapse is common, and treatment options following relapse remain limited with poor outcomes. This highlights the urgent need for new therapeutic approaches that Imdylltra (搜索) aims to address through its targeted immunotherapy mechanism.
Safety Profile and Management Considerations
The most significant safety concern with Imdylltra (搜索) is cytokine release syndrome (搜索) (CRS), an immune reaction caused by rapid release of inflammatory cytokines into the bloodstream. CRS can manifest as fever, low blood pressure, and breathing difficulties, and can be life-threatening. Another serious adverse event is immune effector cell-associated neurotoxicity syndrome (搜索) (ICANS), which causes brain inflammation leading to confusion and difficulties with speaking and walking.
Due to the severity of these potential complications, early recognition and treatment are critical. The product information will include detailed descriptions of these risks and management guidance. All patients will receive a patient card informing them about CRS and ICANS symptoms and when to seek urgent medical attention.
Other common side effects include decreased appetite, fever, taste disturbances, constipation, anemia, fatigue, nausea, weakness, neutropenia, low blood sodium levels, headache, and lymphopenia.
Commercial Success and Market Impact
According to Amgen, Imdelltra has rapidly become the standard of care for patients with second-line or later SCLC (搜索), with sales rising to $627 million in the most recent year, up from $115 million in the previous year. The drug received full FDA approval in November following earlier accelerated approval status.
Regulatory Pathway Forward
The CHMP opinion represents an intermediary step toward patient access in the European Union. The recommendation will now proceed to the European Commission for adoption of an EU-wide marketing authorization decision. Following marketing authorization, individual member states will make decisions regarding pricing and reimbursement based on the drug's potential role within their respective national health systems.